Semaglutide's European Patent Cliff Isn't Here Yet

A Dutch court blocks a compounded nasal spray, showing Novo Nordisk's exclusivity runs to 2031.

6 Aug 2026

Headlines have been declaring semaglutide's patent cliff for months. A Dutch ruling suggests the obituary was premature. The District Court of The Hague granted Novo Nordisk a preliminary injunction against Ceban Ziekenhuisfarmacie, a pharmacy in Breda, finding it had infringed the company's supplementary protection certificate by preparing and distributing an unapproved nasal spray version of the drug.

The underlying compound patent covering semaglutide expired across Europe in March. That fact generated global coverage describing a broad cliff for the molecule. The description holds in markets governed by compound patents alone, including India, Brazil, and China, where generic manufacturers have moved quickly.

Much of the European Union tells a different story. A separate country-specific exclusivity instrument extends Novo Nordisk's protection well beyond the underlying patent, keeping the Netherlands locked in until March 2031. That distinction has been easy to miss amid the broader patent-cliff narrative.

The court found that the pharmacy, which marketed the spray under the brand name Semanova, had prepared the product in 2025 and supplied it both directly to patients and to other pharmacies. It had also listed the product in the Dutch prescribing database used nationwide by general practitioners. Judges rejected the pharmacy's defense that a legal exemption for compounded medicines applied.

Evidence pointed to commercial motivation rather than an unmet medical need such as needle aversion, judges found. The ruling orders the pharmacy to halt distribution immediately, withdraw the product from prescribing systems, recall stock already supplied elsewhere, and disclose its supply chain, including the identity of its API supplier.

Biosimilar and generic manufacturers across multiple continents are preparing for looser intellectual property protection on early GLP-1 molecules. For patients and competitors watching the semaglutide cliff unfold, the ruling is a reminder worth heeding.

Headline patent-expiry dates and the actual date exclusivity ends in a given country can differ by years. That gap carries direct consequences for when genuinely cheaper obesity treatments reach the region.